ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT EBITDA Margin

EBITDA as a percentage of revenue.

ADC Therapeutics S.A.NYSE: ADCT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -98.3%

EBITDA Margin was -98.3% in Q1 FY2026, up 13.2 pp from a year earlier. On a trailing-twelve-month basis it was -105.1%, up 22.1 pp year over year. Over 3 fiscal years it narrowed by 58.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -45.9% for the fiscal year ending Dec 2026, up from -109.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-98.3%-125.7 pp QoQ
Last fiscal yearDec 2025
-109.7%+35.2 pp YoY
LTMMar 2026
-105.1%+22.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+13.2 pp+115.2 pp+102.0 pp
1 year+35.2 pp+63.8 pp+28.6 pp
3 years-58.4 pp+113.7 pp+172.1 pp
5 years+138.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-109.7%
Year-over-year change
+35.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's LTM Mar 2026 EBITDA Margin of -105.1% is the 3rd highest of the 9 companies compared; the peer median is -270.6%.
  • Its year-over-year change of +22.1 pp is the 5th highest of 8, against a peer median of +470.9 pp.
  • Over three fiscal years its change of -58.4 pp compares with a peer median of +1803.8 pp.
ADCT Competitors Peer median
EBITDA Margin for ADCT and competitors
Company Period LTM level YoY 3-year change
OMEROmeros CorporationLTM Mar 2026939.0% ——
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-25.0% +470.9 pp+71883.1 pp
ADCTADC Therapeutics S.A.LTM Mar 2026-105.1% +22.1 pp-58.4 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-185.2% +738962.6 pp+3203.1 pp
AUTLAutolus Therapeutics plcLTM Mar 2026-249.3% +2401.7 pp+1803.8 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-291.9% -129.0 pp-296.2 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-333.1% +482.9 pp+448.9 pp
QSIQuantum-Si incorporatedLTM Mar 2026-5352.8% -2558.8 pp—
ALMSAlumis Inc. Common StockLTM Jun 2026-5986.3% -3970.2 pp—
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ADCT) -270.6%+470.9 pp+1803.8 pp

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.92M209.91M69.56M70.84M81.36M
Cost of Revenue1.39M3.3M2.53M5.95M7.67M
Gross Profit32.52M206.61M67.03M64.89M73.68M
Gross Margin95.9%98.4%96.4%91.6%90.6%
Research & Development158M186.46M127.13M109.63M104.01M
Selling, General & Admin136.24M143.49M105.89M85.91M(6.82M)
Operating Expenses294.24M329.95M233.02M195.54M182.06M
Depreciation & Amortization2.63M2.39M3.27M3.28M1.88M
EBITDA(230.54M)(107.7M)(145.83M)(102.65M)(89.27M)
EBITDA Margin-679.7%-51.3%-209.6%-144.9%-109.7%
Operating Income(261.72M)(123.34M)(165.99M)(130.65M)(108.38M)
Operating Margin-771.6%-58.8%-238.6%-184.4%-133.2%
Interest Income66K2.57M10.54M12.27M8.81M
Interest Expense18.34M36.73M46.33M50.21M51.63M
Other Income / Expenses10.22M(33.56M)(34.96M)(27.03M)(34.4M)
Income Before Tax(251.51M)(156.9M)(200.95M)(157.68M)(142.78M)
Pre-Tax Margin-741.5%-74.7%-288.9%-222.6%-175.5%
Income Tax Expense(21.48M)227K39.11M166K(157K)
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Net Margin-678.2%-74.9%-345.1%-222.8%-175.3%
EPS (Basic)(3.00)(1.99)(2.94)(1.62)(1.12)
EPS (Diluted)(3.00)(1.99)(2.94)(1.62)(1.12)
Weighted Avg Shares76.75M78.15M81.71M97.16M127.07M
Weighted Avg Shares (Diluted)76.75M78.15M81.71M97.16M127.07M

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.